PBRM1 and renal cell adenocarcinoma: Thus, our study shows a new research direction for improving the immune efficacy of RCC in PBRM1 wild‐type patients and greatly improves the possibility of using targeted peptides in the clinical treatment of PBRM1 wild‐type patients.